

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

---

**SCHEDULE 14D-9**

**SOLICITATION/RECOMMENDATION STATEMENT  
UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934**

---

**Deciphera Pharmaceuticals, Inc.**

(Name of Subject Company)

---

**Deciphera Pharmaceuticals, Inc.**

(Name of Persons Filing Statement)

---

**COMMON STOCK, PAR VALUE \$0.01 PER SHARE**  
(Title of Class of Securities)

**24344T101**  
(CUSIP Number of Class of Securities)

**Steven L. Hoerter**  
**President & Chief Executive Officer**  
**Deciphera Pharmaceuticals, Inc.**  
**200 Smith Street**  
**Waltham, MA 02451**  
**(781) 209-6400**

*With copies to:*

**Stuart M. Cable, Esq.**  
**Lisa R. Haddad, Esq.**  
**James Ding, Esq.**  
**Richard A. Hoffman, Esq.**  
**Sarah Ashfaq, Esq.**  
**Goodwin Procter LLP**  
**100 Northern Avenue**  
**Boston, MA 02210**

**(617) 570-1000**  
(Name, address, and telephone numbers of person authorized to receive notices and communications  
on behalf of the persons filing statement)

---

Check the box if the filing relates solely to preliminary communications made before the commencement of a tender offer.

The information set forth under Items 1.01, 8.01 and 9.01 of the Current Report on Form 8-K filed by Deciphera Pharmaceuticals, Inc. on April 29, 2024 (including all exhibits attached thereto) is incorporated herein by reference.

---

---